BOULDER, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced in partnership with Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, a webinar to present the newest trends in proteomics for biomarker discovery and translational research. The webinar entitled “A New Era in Precision Medicine - Uncovering the Depth & Breadth of the Plasma Proteome with Novel Proteomic Technologies” will be presented by Robert Georgantas, III, PhD, Senior Vice President, Research and Translational Science at Biodesix and Daniel Hornburg, PhD, Principal Scientist from Seer. The webinar is scheduled at 11:00 am ET, Tuesday June 22, 2021 and participants are encouraged to REGISTER HERE.
Proteomics is the next frontier in biomarker and translational research with new emerging technologies that are enabling researchers to see deeper and broader into the plasma proteome than ever before. Biodesix is a recognized leader in profiling patients’ immune response to all cancer types using blood-based solutions that combine proteomic and genomic insights with a proprietary AI analytics platform.
The webinar will include an overview of Seer’s Proteograph™ Product Suite, which uses proprietary engineered nanoparticles to survey plasma proteins, allowing researchers to identify and quantitate proteins across the dynamic range of the proteome. Additionally, learnings will be shared on how the Seer Proteograph Product Suite will help define the biological underpinnings of tests created by Biodesix and how it is being integrated into the Biodesix mass spectrometry-based workflows for biopharmaceutical and academic research.
About Biodesix
Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung, including three proteomic tests. Biodesix launched the Bio-Rad SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab and the cPass SARS Cov-2 Neutralization Antibody Test in response to the global pandemic caused by SARS-CoV-2, the virus that impacts the lung and leads to COVID-19. The antibody tests can detect antibodies that are generated both from infection by the virus and from the vaccines. The blood-based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 36 hours, expediting time to treatment. The blood-based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT™ tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’s most recent annual report on Form 10K, filed March 16, 2021. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
